JENA ACQUISITION Corp II

These disclosures establish the baseline trust value, fix the shareholder redemption price mechanics at $10.00 per public share as initially anticipated, and lock the sponsor's equity alignment ahead of the target search phase. The heavy deferred compensation obligations—specifically a $6,900,000 deferred underwriting fee and a separate $6,900,000 advisory fee—create a structural hurdle for the management team, tying their compensation strictly to deal success rather than time elapsed. The audited balance sheet confirms the Company holds $1,751,508 in operating cash and $15,800 in prepaid expenses against $14,164,485 in liabilities, resulting in a reported shareholders' deficit of $(12,397,177) due to the accounting treatment of the redeemable public shares. Furthermore, the Company explicitly states as of May 30, 2025, that it has not selected any business combination target and has engaged in no substantive discussions with any target, confirming the blank check status. Chief Financial Officer Amanda G. Sturgeon signed the report on June 5, 2025.

This filing establishes the foundational trust account value ($10.00 per share) and the 24-month deadline (May 30, 2027) for the business combination. It also sets lock-up periods: founder shares (Class B) are locked up until one year after the business combination (or earlier if price >= $12.00 for 20/30 days after 150 days); private placement units are locked up for 30 days after the business combination. The sponsor's private placement provides additional working capital. The management team, led by William P. Foley II and Richard N. Massey, indicates a focus on businesses that can benefit from their historical areas of expertise. Investors should track the trust value, deadline, and any future extension votes or deal announcements.

This filing sets the baseline trust value ($10.00 per share), redemption mechanics, and deadline. It details the sponsor's nominal cost ($0.004 per founder share), creating a significant dilution risk and potential conflict of interest. It also outlines the structure of rights, lock-up provisions, and the sponsor's indemnification obligations. Investors use this to understand the SPAC's terms before trading begins.

For a searching SPAC, this filing establishes the baseline IPO terms that will drive future trust value and timing: $200.0 million will be deposited in trust at $10.00 per unit, or $230.0 million if the over-allotment option is exercised in full; the completion window is 24 months from closing of the offering; the sponsor paid $25,000 for 5,750,000 founder shares at approximately $0.004 per share; the sponsor will buy 225,000 private placement units for $2,250,000; the underwriter receives $0.30 per unit deferred underwriting compensation plus a 3% advisory fee; and the sponsor affiliate will be paid $2,500 per month for administrative services. It also discloses that 10,000 founder shares were transferred to each independent director nominee. No target has been identified, so no deal progress or redemption deadline change is reported.

Disclosure conflicts over sponsor equity allocations and recurring administrative fees typically delay S-1 effectiveness or requested acceleration under Rules 460 and 461, keeping capital in trust until the SEC clears the amendments. Until resolution, Jena Acquisition Corporation II cannot consummate a business combination, which maintains shareholder redemption rights and defers any vote on target valuation or sponsor track record. Correcting these disclosures ensures that future investors receive unambiguous data on promoter compensation and operational costs when evaluating redemption thresholds and merger terms.

This document sets the fundamental terms for a $200 million SPAC IPO. All sponsors and officers agree not to redeem their securities. The deadline is 24 months. The dilution disclosure shows that, under a maximum-redemption scenario, public shareholders would incur 109.50% dilution. The SPAC has extensive experience drawing on the track record of co-founders William P. Foley II and Richard N. Massey, including multiple prior SPACs. Despite being a new SPAC, the detailed disclosure in this S-1 provides investors a baseline for tracking future amendments, trust account balances, and extension votes.

The amendments finalize pre-effectiveness terms that directly govern the SPAC’s 2027-05-30 search timeline and shareholder redemption calculus. Explicit extension limitation disclosures clarify deadline flexibility and sponsor penalty exposure, while the mandated $5,000 monthly affiliate payment establishes a recurring operational cost that reduces net trust proceeds available at closing. The trust account interest usage clarification addresses liquidity mechanics that dictate actual cash outflows upon business combination execution and informs redemption floor expectations. These compliance-driven revisions remove regulatory ambiguity ahead of proxy distribution and anchor the capital structure assumptions investors will apply during the redemption vote.

These comments define the legal boundaries for shareholder redemption windows and trust capital deployment. Clarifying extension parameters and sponsor failure consequences determines how long capital remains at risk before liquidation triggers. Resolving the trust-versus-escrow funding mechanic explains whether post-combination valuations depend on third-party debt or existing cash reserves. The mandated $5,000 monthly sponsor affiliate payment discloses recurring operating costs associated with the SPAC shell during the extended search period, which reduces net proceeds available for target acquisition and establishes baseline related-party transactions that will require shareholder approval or valuation scrutiny.

First public disclosure of JENA II's structure and sponsor background. Investors can evaluate the management team (William P. Foley II and Richard N. Massey) with prior SPAC experience including CF Corp, Foley Trasimene I/II, Trebia, Austerlitz I/II. Key terms include 20% founder share ownership, rights requiring 20 rights for one share, anti-dilution adjustments, and the ability to extend the deadline with shareholder approval. The nominal sponsor cost ($0.004/share) creates potential incentive conflicts. The filing is preliminary and not yet effective.

What changed: A routine compliance exhibit — an amended Schedule 13G beneficial ownership report filed by Bank of Montreal, Bank of Montreal Holding Inc., and BMO Nesbitt Burns Inc. The excerpt notes an update to a prior disclosure but provides no quantified data on share acquisitions, aggregate holdings, voting power allocations, or exemption basis modifications. Consequently, the precise mechanical shift in ownership position remains undisclosed within the provided text. Why it matters: Investors monitoring JENA ACQUISITION Corp II’s May 30, 2027 deadline, trust distribution mechanics, extension protocols, deal progression, or sponsor oversight will find no operative language addressing those parameters. The filing does not signal redemption elections, blockholder coordination, target announcement timelines, or charter amendments. Furthermore, the document contains no attributed assertions regarding customer concentration, revenue streams, addressable market sizing, strategic roadmaps, proprietary technology, partnership arrangements, pending litigation, or executive personnel changes. Because the excerpt advances zero verifiable claims or numeric thresholds, and every factual placeholder defaults to the filers’ administrative categorization alone, the submission reflects standard regulatory housekeeping without independent catalyst weight.

What changed: A Schedule 13G/A filing reporting beneficial ownership pursuant to Section 13(d) of the Securities Exchange Act of 1934. Barclays PLC identifies itself as the reporting holder of the registrant’s shares. The submitted text provides no share quantities, ownership percentages, transaction dates, or comparative data from earlier filings to show what changed. Why it matters: The filing does not disclose any updates to JENA’s trust account composition or per-share value, its business combination deadline (2027-05-30), extension voting procedures, shareholder redemption elections, or sponsor conduct. It contains no claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel attributed to the company, its sponsors, management, or other parties.

What changed: Quarterly report (Form 10-Q) for the quarterly period ended September 30, 2025, filed on November 14, 2025, by Jena Acquisition Corporation II, a blank-check SPAC that completed its IPO on May 30, 2025. Trust account grew to $233,179,788 ($10.14 per share) from the initial $230,000,000 ($10.00 per share) due to interest income. No definitive business combination agreement has been entered into; the company is still searching. No extension of the Combination Period (deadline May 30, 2027) has been proposed. Working capital of $1,127,460 is sufficient for at least one year. No new Working Capital Loans. Advisory fee payable of $6.9M and deferred underwriting fee of $6.9M remain contingent on a deal. Why it matters: This is the company's first quarterly report since its IPO, providing baseline financials. The trust value per share ($10.14) exceeds the redemption price, offering a modest buffer for shareholders. The absence of a target or extension confirms the company is early in its search period. Sponsor conduct remains standard; no related-party transactions beyond the administrative services agreement. The filing contains no new risk factors or litigation.

What changed: Schedule 13G, a routine compliance exhibit and regulatory beneficial ownership report disclosing that Barclays PLC holds equity securities in JENA. Barclays PLC is identified as the reporting holder. The provided excerpt contains no share quantity, acquisition date, purchase price, percentage owned, or statement of purpose, and therefore introduces no updated parameters regarding redemption thresholds, trust fund preservation, extension votes, target identification progress, or sponsor conduct. Why it matters: Institutional investors frequently file these disclosures when crossing ownership reporting triggers, but without disclosed block sizes, pricing, or strategic intent, the filing alone does not indicate shifts in capital commitment, deal pacing, or governance posture relative to the firm’s search timeline. Assertions regarding Barclays PLC’s position are derived exclusively from the holder designation within the filing itself.

What changed: A routine compliance exhibit (Joint Filing Agreement, Exhibit A) attached to a Schedule 13G/A beneficial ownership report. The document reports no updates to redemption deadlines, trust valuation, extension schedules, merger deal progress, or sponsor conduct. It also contains no substantive claims about customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel. The filing simply records that Linden Capital L.P., Linden GP LLC, Linden Advisors LP, and Siu Min Wong agreed to file a single Schedule 13G/A on behalf of all four parties pursuant to Rule 13d-1(k), referencing an underlying statement dated November 11, 2025 and a historical power of attorney dated June 10, 2019. Why it matters: Because it lacks operational, financial, or corporate action disclosures, this exhibit does not advance or delay the SPAC’s search phase, modify shareholder redemption mechanics, or alter the May 30, 2027 termination date. Investors tracking capital call windows, trust interest accruals, or target announcement deadlines should disregard this attachment for timeline purposes and instead consult the main Schedule 13G/A summary for actual ownership percentages and any basis-of-ownership amendments.

What changed: Quarterly report (Form 10-Q) for a blank-check SPAC in its searching phase, its first 10-Q since the IPO closed on May 30, 2025. First financial statements post-IPO: trust funded at $230 million ($10.03 per share), $6.9M advisory fee accrued (contingent on deal), $1.19M working cash. No target identified, no substantive discussions. Sponsor transferred founder shares to directors; sponsor loan fully repaid. Why it matters: Establishes baseline trust value ($10.03/sh) and 24-month deadline (May 2027). Highlights non-cash advisory liability and limited sponsor indemnification capacity. Confirms the SPAC is still searching, with no deal progress.

What changed: Schedule 13G beneficial ownership report. The filing discloses that Barclays PLC holds a beneficial ownership interest in JENA Acquisition Corp II. The excerpt provides no share quantity, purchase price, or investment purpose, so there is no update to the SPAC’s trust value, redemption deadline, extension status, or sponsor conduct. Why it matters: A Schedule 13G typically signals institutional capital allocation at or above the five percent threshold during the SEARCHING phase, but Barclays PLC attributed no operational claims, customer metrics, revenue projections, technology roadmap details, partnership terms, litigation matters, or personnel changes to this submission. Without further amendments or accompanying proxies, this compliance filing does not materially alter the entity’s trajectory or timeline.

What changed: Schedule 13G — beneficial ownership report. The filing identifies Bank of Montreal, Bank of Montreal Holding Inc., and BMO Nesbitt Burns Inc. as reporting their beneficial ownership positions in Jena Acquisition Corp II as of the 2025-07-31 filing date. The provided excerpt omits share quantities, percentage thresholds, acquisition or disposition dates, and transaction pricing. Why it matters: This is a routine institutional ownership disclosure that does not alter Jena’s SEARCHING status, affect trust distribution mechanics, impact the 2027-05-30 redemption deadline, signal extension approvals, indicate target negotiation progress, or reflect sponsor governance actions. The document contains no statements regarding customers, revenue, market size, strategic direction, technology, partnerships, litigation, or executive appointments. No individual or entity attributed any operational or financial claims within the text, leaving no material data points for redemption modeling or merger diligence at this time.

What changed: a Schedule 13G joint filing agreement for beneficial ownership reporting under Rule 13d-1(k). The filing does not modify JENA ACQUISITION Corp II’s redemption deadline, trust account value per share, extension mechanics, target search status, or sponsor conduct. As executed on July 25, 2025, and filed on 2025-07-28 under SEC docket 0000950170-25-098960, it simply records that Linden Capital L.P., Linden GP LLC, Linden Advisors LP, and Siu Min Min Wong agree to submit future amendments to their Schedule 13G statements on a joint basis. Saul Ahn is designated as the authorized signatory for the corporate entities and as attorney-in-fact for Siu Min Min Wong under a Power of Attorney dated June 10, 2019. No changes to capital structure, voting thresholds, or acquisition timelines are disclosed. Why it matters: Beyond confirming a routine aggregation of existing shareholder interests to satisfy Exchange Act reporting obligations, the document contains no substantive business, financial, or operational disclosures. It makes no claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel. A cross-reference notes a prior 2019 filing (June 19, 2019) regarding holdings in Haymaker Acquisition Corp II, but offers no valuation data, target pipeline indicators, or SPAC-specific covenants. For investors monitoring redemption windows or trust movements, the filing provides zero new terms, revised calendars, or sponsor behavior updates; its utility is strictly limited to verifying that the named affiliates act collectively for regulatory disclosure purposes.

What changed: A routine compliance exhibit and press release attached to an 8-K current report. According to the July 16, 2025 press release included as Exhibit 99.1, holders of units issued in the initial public offering may elect to separately trade the Class A ordinary shares and share rights within those units, commencing July 21, 2025. Each unit comprises one Class A ordinary share, par value $0.0001 per share, and one right to receive one-twentieth (1/20) of one Class A ordinary share upon the consummation of the company’s initial business combination. Separated shares will trade on the New York Stock Exchange under the symbol "JENA," separated rights under "JENA.R," and unseparated units will continue under "JENA.U." Holders must direct their brokers to contact transfer agent Continental Stock Transfer & Trust Company to execute the separation. The filing contains zero updates regarding the May 30, 2027 redemption deadline, trust account mechanics, extension procedures, target deal progress, or sponsor conduct. Why it matters: Decoupling the equity and derivative components establishes independent trading channels, improving liquidity and allowing shareholders to price or hedge the fractional share rights separate from the base stock prior to a merger announcement. This administrative step does not modify the contractual triggers for cash redemptions, alter the timeline for trust fund payouts, or accelerate/decelerate the merger process. Regarding non-mechanical substance, the filing reconfirms the registrant is a Cayman Islands exempted blank check company organized to effect a merger, share exchange, asset acquisition, or similar business combination. The press release attributes the company's strategic posture to its principals, stating management intends to capitalize on its leadership's capabilities and "initially focus its search on identifying a prospective target business that can benefit from [co-founder and Chairman] William P. Foley, II’s and [co-founder and Chief Executive Officer] Richard N. Massey’s historical areas of business expertise." The document makes no assertions regarding customers, revenue, market size, technology, partnerships, or active litigation.